ArticleGeneral psychiatry2025
Resonant breathing in hospitalised psychiatric patients with persistent somatic symptoms: a randomised controlled trial.
Article in General psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent somatic symptoms are a common feature in many psychiatric disorders. Moderate-to-severe cases often necessitate treatment in specialised inpatient psychiatric settings. Aims: This study evaluated the efficacy, safety and acceptability of resonant breathing (personalised slow breathing to maximise heart rate variability (HRV)) as adjunctive treatment for hospitalised patients with psychiatric disorders presenting with persistent somatic symptoms on admission, when patients typically present with high symptom severity. Methods: This multicentre, randomised, placebo-controlled cross-over study included 78 patients diagnosed with somatic symptom disorder or affective disorders with persistent somatic symptoms. Participants underwent light-guided resonant breathing and sham light therapy two times per day for 5 weekdays each, starting an average of 11 days after admission. The primary outcomes were changes in self-reported somatic well-being and arousal (efficacy), and adverse effects (safety). Secondary outcomes included somatic, anxiety, depression and insomnia symptoms, HRV measures and patient satisfaction (acceptability). The trial was preregistered in the German Clinical Trial Register (ID: DRKS00027323) and funded by the Austrian Research Promotion Agency (Grant ID. F0999886082). Results: Resonant breathing rates were six breaths per minute in 60% of patients and higher in the remaining participants. The study found no intervention-specific effect on primary outcomes of self-reported somatic well-being and arousal. Patients reported no adverse effects and expressed high satisfaction with the breathing intervention. Resonant breathing significantly reduced secondary outcomes of self-reported anxiety (η² Conclusions: While resonant breathing did not improve somatic well-being or arousal, it was safe, well-tolerated and effective at reducing anxiety and insomnia symptoms during early hospitalisation. These findings support further investigation into resonant breathing for these specific indications over extended periods. Trial registration number: DRKS00027323.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.